Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (SEHK: 2566)
Health Care · Biotechnology · CN
HK$5.41
+2.95% today · -65.4% 1Y
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (SEHK: 2566) operates in the Biotechnology industry within the Health Care sector. The company is valued at $166.50M and employs 1,794 people.
Over the last twelve months the share price has lost 65.4%, trading between 4.60 and 16.29.
Tweenvest scores Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. across four factors: quality 69/100, value 80/100, dividend 48/100. Its strongest factor is value.
2566 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $166.50M
- Revenue (TTM)
- $186.76M
- P/E
- 8.62
- EPS
- 0.56
- Dividend yield
- 1.21%
- Beta (5Y)
- —
- 52-week high
- HK$16.29
- 52-week low
- HK$4.60
- Avg volume (3M)
- —
- Shares outstanding
- 241.52M
- Employees
- 1,794
- Next earnings
- —
About Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, manufacturing, and commercialization of biopharmaceutical products and medical devices in Mainland China and internationally. The company offers Guyoudao, a bone repair material; Jilifen, a human granulocyte colony stimulating factor injection; Jijufen, a human interleukin-11 injection; Jiouting, a palonosetron hydrochloride injection; Jifuwei, a fulvestrant injection; Jitansu, a fosaprepitant dimeglumine injection; and Jixinfen, PEG-GCSF injection. It also provides Jilixin avatrombopag maleate tablets; Jipailin, a low molecular weight heparin sodium injection; and Yinuojia, an enoxaparin sodium injection. The company was formerly known as Hangzhou Jiuyuan Gene Engineering Co., Ltd. and changed its name to Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. in April 2025. Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. was incorporated in 1993 and is headquartered in Hangzhou, China.
- ISIN
- CNE100006KF0
- Founded
- 1993
- Listed since
- Nov 28, 2024
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.